{
    "organizations": [],
    "uuid": "79537db37dc58e7dbc812c2a2812cdfa94191a7d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-immune-pharma-presents-positive-re/brief-immune-pharma-presents-positive-results-from-phase-2-trial-of-bullous-pemphigoid-treatment-idUSASC0A2BF",
    "ord_in_thread": 0,
    "title": "BRIEF-Immune Pharma Presents Positive Results From Phase 2 Trial Of Bullous Pemphigoid Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - Immune Pharmaceuticals Inc:\n* IMMUNE PHARMACEUTICALS PRESENTS UPDATED POSITIVE RESULTS FROM PHASE 2 TRIAL OF BERTILIMUMAB IN BULLOUS PEMPHIGOID\n* IMMUNE PHARMACEUTICALS INC - POSITIVE DATA SUPPORT COMPANY’S PLANS TO COMMENCE PIVOTAL REGISTRATION STUDY IN 2019\n* IMMUNE PHARMACEUTICALS INC - RESULTS FROM ALL SUBJECTS CONFIRM “EXCELLENT” SAFETY AND TOLERABILITY Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-15T21:14:00.000+03:00",
    "crawled": "2018-05-16T18:47:04.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "immune",
        "pharmaceutical",
        "inc",
        "immune",
        "pharmaceutical",
        "present",
        "updated",
        "positive",
        "result",
        "phase",
        "trial",
        "bertilimumab",
        "bullous",
        "pemphigoid",
        "immune",
        "pharmaceutical",
        "inc",
        "positive",
        "data",
        "support",
        "company",
        "plan",
        "commence",
        "pivotal",
        "registration",
        "study",
        "immune",
        "pharmaceutical",
        "inc",
        "result",
        "subject",
        "confirm",
        "excellent",
        "safety",
        "tolerability",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}